Kinase assays

Pak1 (571 nM final) in Assay buffer was mixed with IPA-3 for 5 min at room temp, followed by addition of 4 μM Cdc42 and 8.3 μM MBP for an additional 5 min. Kinase reactions were started by addition of unlabeled ATP and 1–10 μCi [32P]-γ-ATP per reaction for 10 min at 30°C. Kinase reactions were stopped on dry ice. Under these conditions, MBP phosphorylation was linear with time.

Cell lines

Mouse embryonic fibroblasts

Preparation method

The solubility of this compound in DMSO is >16.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

30 μM for 10 min

Applications

IPA-3 selectively inhibits Pak1 activation in mammalian cells, and can inhibit activation of Group I Paks in cells.

Animal models

CD-1 mice

Dosage form

3.5 mg/kg, i.p.

Application

Inhibition of PAK1 by IPA-3 promoted recovery of neurological function, possibly by downregulating the expression of MMP-2, MMP-9, TNF-α, and IL-1β. IPA-3 may be a potential therapeutic drug for spinal cord injury.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Deacon S W, Beeser A, Fukui J A, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chemistry & biology, 2008, 15(4): 322 - 331.

[2] Ji X, Zhang Y, Zhang L, Chen H, Peng Y, Tang P. Inhibition of p21-Activated Kinase 1 by IPA-3 Promotes Locomotor Recovery After Spinal Cord Injury in Mice. Spine (Phila Pa 1976). 2016 Jun;41(11):919-25.